Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Ryght AI tackles these hurdles with its AI Site Twin platform
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
This launch is part of the company's strategy to expand its nutraceutical portfolio
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
Subscribe To Our Newsletter & Stay Updated